Pfizer pays $15m advance on PhIII milestone for sickle cell drug
This article was originally published in Scrip
Executive Summary
Relief for GlycoMimetics as Pfizer pays up $15m of the $35m milestone payment which was due on the start of a Phase III of the drug candidate rivipansel (GMI-1070). Pfizer however has yet to disclose when the trial of the sickle cell disease treatment will actually begin.